FAW Teams up with RoboSense on The World’s First Automotive-grade Solid-state Smart LiDAR Sensor for Serial Production
RoboSense, the pioneering Smart LiDAR Sensor provider, announced a partnership with FAW ("First Automobile Works"), the world's leading automotive OEM (Original Equipment Manufacturer), and showcased the milestone achievement of last year’s cooperation: the first batch of world’s first solid-state Smart LiDAR Sensor RS-LiDAR-M1 on September 25. The deal is to include RS-LiDAR-M1 as core component into FAW's proprietary next-generation autonomous driving system development, therefore accelerating the serial production of the world's first automotive-grade solid-state MEMS-based Smart LiDAR Sensor, in order to promote Level 3 vehicle autonomy and above.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190927005229/en/
FAW Teams up with RoboSense on The World’s First Automotive-grade Solid-state Smart LiDAR Sensor for Serial Production (Photo: Business Wire)
The final commercialized version of RS-LiDAR-M1 is the world’s first and only all-in-one unit MEMS-based Smart LiDAR Sensor for self-driving passenger vehicles with its own embedded AI algorithm technologies and SoC (System of Chip). It transforms traditional LiDAR systems (also known as solely data collectors), to full data analysis and comprehension systems. The RS-LiDAR-M1 not only collects and interprets high definition 3D point cloud data, but its built-in AI algorithm and SoC also process road data in real-time, while at the same time synchronizing outputs of high-precision localization, obstacle detection, tracking and classification, road curbs and driving areas detection.
Unlike RoboSense Smart LiDAR Sensor, when mechanical LiDAR is used on a vehicle, a computer-sized ECU must also be used to operate the algorithms. Compared with ECUs, the RoboSense dedicated SoC built into the Smart LiDAR Sensor not only withstands strong bumps and jolts in the vehicle, but is also small and light-weight. The RoboSense Smart LiDAR Sensor's built-in SoC can largely reduce more power consumption while improving performance compared to automotive ECUs, saving much more passenger space at the same time.
The RS-LiDAR-M1 is cleanly designed in a streamlined body that allows it to be easily embedded onto any part of the vehicle for the complete aesthetics of automobile.
Serial produced RoboSense Smart LiDAR Sensor costs only hundreds of dollars each, based on its deployment of revolutionary MEMS micro-mirror scanning structure and simplified manufacturing and streamlines production, while maintaining high product quality and reliability to meet exacting OEM requirements.
Fengjun Li, Director of Intelligent Connected Vehicle Development Institute, FAW, said, "China is standing at the front of the world's autonomous driving development. Our cooperation with RoboSense demonstrates our confidence in Smart LiDAR Sensor for Level 3 vehicle autonomy and above, and accelerates the commercialized development of our proprietary next-generation autonomous driving system”.
"The RS-LiDAR-M1 is a revolutionary product developed upon more than ten years of research development accumulated by the RoboSense team. We believe the partnership will enhance the serial production ability of automotive-grade Smart LiDAR Sensor for autonomous driving,” said Steven Qiu ChuanXin, RoboSense Founder and CEO.
At the signing ceremony, the closest to commercialized version of Smart LiDAR Sensor RS-LiDAR-M1 delivered by RoboSense will be used for FAW's automotive-grade testing and self-driving passenger cars research development. The current version has greatly improved performance while reducing the size to only the half of the former demo showcased on CES 2019, which can be easily integrated into any part of the vehicle body. More details of the latest version will be coming soon.
About RoboSense:
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the first and only MEMS-based Smart LiDAR Sensor for autonomous driving.
For more information about RoboSense please visit: https://www.robosense.ai/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190927005229/en/
Contact information
Media:
Cassie Gong, PR Manager
sqgong@robosense.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 11:53:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 11:00:00 EET | Press release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 11:00:00 EET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 09:30:00 EET | Press release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom